Practice and thinking on the traditional Chinese medicine treatment of chronic atrophic gastritis based on pathological evaluation
DOI:
https://doi.org/10.54844/gmiw.2022.0091Keywords:
Chronic atrophic gastritis; Precancerous lesions of the stomach; Pathological histology; Chinese medicine interventionAbstract
Chronic atrophic gastritis is a precancerous gastric disease with intestinal epithelial hyperplasia and heterogeneous proliferation based on mucosal atrophy. In recent years, the international guidelines and consensus on the treatment of precancerous gastric disease have been gradually updated, emphasizing the treatment of precancerous gastric disease and lesions based on the pathological changes as the outcome. Chinese medicine is widely used in the clinical treatment of chronic atrophic gastritis, but there are fewer research ideas of Chinese medicine based on the pathological evaluation of the results. In this article, the pathological concepts related to chronic atrophic gastritis and the clinical research ideas and practice strategies of traditional Chinese medicine based on the evaluation of pathological outcomes are compiled.
References
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161-1181. [PMID:8827022 DOI:10.1097/00000478-199610000-00001]
Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet (London, England). 1975;2(7924):58-60. [PMID:49653 DOI:10.1016/s0140-6736(75)90498-5]
Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867. [PMID:26215280 DOI:10.1136/bmj.h3867]
Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut. 2003;52(8):1111-1116. [PMID:12865267 DOI:10.1136/gut.52.8.1111]
Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367. [PMID:26187502 DOI:10.1136/gutjnl-2015-309252]
Kono S, Gotoda T, Yoshida S, et al. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World J Gastroenterol. 2015;21(46):13113-13123. [PMID:26673849 DOI:10.3748/wjg.v21.i46.13113]
Liu Y, Uemura N, Xiao SD, et al. Agreement between endoscopic and histological gastric atrophy scores. J Gastroenterol. 2005;40(2):123-127. [PMID:15770394 DOI:10.1007/s00535-004-1511-x]
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. [PMID:30841008 DOI:10.1055/a-0859-1883]
El-Zimaity HMT, Ramchatesingh J , Saeed MA .Gastric intestinal metaplasia: subtypes and natural hsitory. J Clin Pathol. 2001, 54(9):679-683. [PMID: 11533073 DOI: 10.1136/jcp.54.9.679]
Piazuelo MB, Camargo MC, Mera RM, et al. Gastric intestinal metaplasia type III and prospective risk of gastric cancer in Colombia. Gastroenterology. 2017;152:S473.
González CA, Pardo ML, Liso JMR, et al. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer. 2010;127(11):2654-2660. [PMID:20178099 DOI:10.1002/ijc.25273]
Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-1575. [PMID:31278206 DOI:10.1136/gutjnl-2018-318126]
Huang D, Zhu XZ, Sheng WQ. Interpretation of gastrointestinal epithelial tumors in the 2019 edition of WHO classification of digestive system tumors. Chin J Pathol. 2020;49:209–213.
Preparatory group of digestive pathology group of pathology branch of Chinese Medical Association. Consensus on pathological diagnosis of gastric mucosal biopsy of chronic gastritis and epithelial tumors. Chin J Pathol. 2017;46:289–293.
Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84(4):618-624. [PMID:26995689 DOI:10.1016/j.gie. 2016.03.791]
Rugge M, Genta RM; OLGA Group. Staging gastritis: an international proposal. Gastroenterology. 2005;129(5):1807-1808. [PMID:16285989 DOI:10.1053/j.gastro. 2005.09.056]
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150-1158. [PMID:20381801 DOI:10.1016/j.gie. 2009.12.029]
Satoh K, Osawa H, Yoshizawa M, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter. 2008;13(3):225-229. [PMID:18466398 DOI:10.1111/j.1523-5378. 2008.00599.x]
den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. 2019;68(4):585-593. [PMID:29875257 DOI:10.1136/gutjnl-2017-314498]
Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999;45(5):784-790. [PMID:10517922 DOI:10.1136/gut.45.5.784]
Sung JK. Diagnosis and management of gastric dysplasia. Korean J Intern Med. 2016;31(2):201-209. [PMID:26932397 DOI:10.3904/kjim. 2016.021]
Srivastava A, Lauwers GY. Gastric epithelial dysplasia: The Western perspective. Dig Liver Dis. 2008;40(8):641-649. [PMID:18424243 DOI:10.1016/j.dld. 2008.02.039]
Fox JG, Wang TC. Helicobacter pylori—not a good bug after all. N Engl J Med. 2001;345(11):829-832. [PMID:11556306 DOI:10.1056/NEJM200109133451111]
Piscione M, Mazzone M, Di Marcantonio MC, et al. Eradication of Helicobacter pylori and gastric cancer: A controversial relationship. Helicobacter pylori. 2021;12:630852. [PMID:33613500 DOI:10.3389/fmicb. 2021.630852]
Kong YJ, Yi HG, Dai JC, et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903-5911. [PMID:24914352 DOI:10.3748/wjg.v20.i19.5903]
Zhou LY, Lin SR, Ding SG, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: A 10-year follow-up study. Chin Med J (Engl). 2014;127(8):1454-1458.
Toyokawa T, Suwaki K, Miyake Y, et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol. 2010;25(3):544-547. [PMID:19817964 DOI:10.1111/j.1440-1746. 2009.05995.x]
Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012;47(4):394-403. [PMID:22138891 DOI:10.1007/s00535-011-0504-9]
Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151(2):121-128. [PMID:19620164 DOI:10.7326/0003-4819-151-2-200907210-00009]
Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. [PMID:24846275 DOI:10.1136/bmj.g3174]
Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018;378(12):1085-1095. [PMID:29562147 DOI:10.1056/NEJMoa1708423]
Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75(1):39-46. [PMID:22018552 DOI:10.1016/j.gie. 2011.08.030]
Takeoka A, Tayama J, Kobayashi M, et al. Psychological effects of Helicobacter pylori‐associated atrophic gastritis in patients under 50years: A cross‐sectional study. Helicobacter 2017;22:12445.
Deng X, Liu ZW, Wu FS, et al. A clinical study of weining granules in the treatment of gastric precancerous lesions. J Tradit Chin Med. 2012;32(2):164-172. [PMID:22876438 DOI:10.1016/s0254-6272(13)60006-0]
Li HZ, Wang H, Wang GQ, et al. Treatment of gastric precancerous lesions with Weiansan. World J Gastroenterol. 2006;12(33):5389-5392. [PMID:16981274 DOI:10.3748/wjg.v12.i33.5389]
Liao WL, Chen GZ, Xia LM. A Meta-Analysis of BanxiaXiexin Decoction in Treatment of Chronic Atrophic Gastritis. Lishizhen Medicine and Materia Medica Research 2014:1526–1529.
Cheng RD, Zhao B, Ma SQ, et al. Meta analysis of benefiting qi for activating blood circulation for the treatment of chronic atrophic gastritis. China J Tradit Chin Med and Pharm. 2017;32(5):166–170.
Xie XM, Ran JC, Zhao WH, et al. Meta-analysis on treatment of chronic atrophic gastritis with TCM based on theory of "Deficiency, Blood Stasis and Toxin". Chin Arch Tradit Chin Med. 2020;38(2):116–122.
Liu FB, Wang WQ. The idea of constructing the theoretical structure model of pro scale for spleen and stomach diseases in traditional Chinese medicine. J Guangzhou Univ Tradit Chin Med. 2008;25:12–14.
Liu L, Chang YS, Shen SW, et al. Development and reliability & validity analysis of patient reported outcome scale f or precancerous lesion of atrophic gastritis. J Tradit Chin Med. 2011;52:834–836.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gut Microbiota and Integrative Wellness
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
